Zacks Research Has Negative Estimate for STERIS Q2 Earnings

STERIS plc (NYSE:STE - Free Report) - Equities researchers at Zacks Research decreased their Q2 2026 earnings per share estimates for shares of STERIS in a research note issued to investors on Wednesday, June 4th. Zacks Research analyst R. Department now anticipates that the medical equipment provider will post earnings per share of $2.35 for the quarter, down from their previous estimate of $2.36. The consensus estimate for STERIS's current full-year earnings is $9.08 per share. Zacks Research also issued estimates for STERIS's FY2028 earnings at $11.93 EPS.

A number of other research analysts have also recently commented on the company. Jefferies Financial Group initiated coverage on STERIS in a research note on Thursday, May 29th. They set a "hold" rating and a $263.00 price objective on the stock. Needham & Company LLC reissued a "hold" rating on shares of STERIS in a research report on Monday, April 7th. Wall Street Zen downgraded shares of STERIS from a "strong-buy" rating to a "buy" rating in a research report on Friday, May 30th. JMP Securities boosted their target price on shares of STERIS from $265.00 to $280.00 and gave the stock a "market outperform" rating in a research report on Friday, May 16th. Finally, Citigroup reaffirmed an "outperform" rating on shares of STERIS in a report on Friday, May 16th. Three equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company's stock. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $263.83.

STERIS Stock Performance

Shares of STE stock opened at $243.17 on Friday. The company's fifty day simple moving average is $229.88 and its 200-day simple moving average is $221.54. The company has a current ratio of 2.13, a quick ratio of 1.40 and a debt-to-equity ratio of 0.32. STERIS has a 52 week low of $200.98 and a 52 week high of $252.79. The company has a market cap of $23.92 billion, a PE ratio of 51.63 and a beta of 0.94.

STERIS (NYSE:STE - Get Free Report) last released its quarterly earnings data on Wednesday, May 14th. The medical equipment provider reported $2.74 EPS for the quarter, topping analysts' consensus estimates of $2.59 by $0.15. STERIS had a return on equity of 13.91% and a net margin of 8.66%. The company had revenue of $1.48 billion for the quarter, compared to the consensus estimate of $1.47 billion. During the same period last year, the business posted $2.58 EPS. The company's quarterly revenue was up 5.7% compared to the same quarter last year.

STERIS Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, June 26th. Stockholders of record on Tuesday, June 10th will be given a $0.57 dividend. This represents a $2.28 annualized dividend and a dividend yield of 0.94%. The ex-dividend date of this dividend is Tuesday, June 10th. STERIS's payout ratio is currently 36.77%.

Insider Activity

In related news, SVP Cary L. Majors sold 12,828 shares of the business's stock in a transaction dated Tuesday, May 20th. The stock was sold at an average price of $250.08, for a total value of $3,208,026.24. Following the completion of the sale, the senior vice president now directly owns 11,372 shares of the company's stock, valued at $2,843,909.76. The trade was a 53.01% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Company insiders own 1.14% of the company's stock.

Institutional Investors Weigh In On STERIS

A number of institutional investors have recently made changes to their positions in STE. Stratos Wealth Partners LTD. raised its holdings in shares of STERIS by 2.5% during the fourth quarter. Stratos Wealth Partners LTD. now owns 15,956 shares of the medical equipment provider's stock worth $3,280,000 after purchasing an additional 390 shares during the period. Mirae Asset Global Investments Co. Ltd. raised its stake in STERIS by 30.8% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 10,970 shares of the medical equipment provider's stock worth $2,275,000 after acquiring an additional 2,583 shares during the period. Tyche Wealth Partners LLC bought a new position in STERIS in the fourth quarter worth about $462,000. Fruth Investment Management bought a new position in shares of STERIS during the fourth quarter valued at approximately $2,420,000. Finally, GHP Investment Advisors Inc. grew its holdings in shares of STERIS by 5.7% during the fourth quarter. GHP Investment Advisors Inc. now owns 59,298 shares of the medical equipment provider's stock valued at $12,189,000 after purchasing an additional 3,213 shares during the last quarter. 94.69% of the stock is currently owned by institutional investors.

STERIS Company Profile

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.